HEMAB THERAPEUTICS HOLDINGS (COAG) Stock Price, News & Analysis
Company Description
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies for blood coagulation disorders. The company focuses on treatments intended to address rare bleeding conditions, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its common stock trades on the Nasdaq Global Select Market under the symbol COAG.
The company's lead program is sutacimig (HMB-001), a bispecific antibody being developed as a prophylactic therapy for Glanzmann thrombasthenia and Factor VII deficiency. Hemab's work is centered on coagulation biology and the development of therapeutic candidates for patients with inherited or rare bleeding disorders.
Hemab reports one operating segment focused on the research and development of prophylactic therapeutics for bleeding disorders. As a clinical-stage biotechnology issuer, its operating model is based on advancing drug candidates through research, development, and regulatory processes before any potential commercialization.
Stock Performance
HEMAB THERAPEUTICS HOLDINGS (COAG) stock last closed at $49.16. At a market capitalization of $2.3B, COAG is classified as a mid-cap stock with approximately 46.7M shares outstanding.
Latest News
HEMAB THERAPEUTICS HOLDINGS has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 2 with negative movement. Key topics include earnings, clinical trial, IPO, offering. View all COAG news →
SEC Filings
HEMAB THERAPEUTICS HOLDINGS has filed 5 recent SEC filings, including 3 Form SCHEDULE 13G, 1 Form 10-Q, 1 Form 8-K. The most recent filing was submitted on August 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all COAG SEC filings →
Insider Radar
Insider buying activity at HEMAB THERAPEUTICS HOLDINGS over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Upcoming Events
Prix Galien Awards Ceremony
HEMAB THERAPEUTICS HOLDINGS has 1 upcoming scheduled event. The next event, "Prix Galien Awards Ceremony", is scheduled for October 29, 2026 (in 66 days). Investors can track these dates to stay informed about potential catalysts that may affect the COAG stock price.
Short Interest History
Short interest in HEMAB THERAPEUTICS HOLDINGS (COAG) currently stands at 2.0 million shares, up 22.9% from the previous reporting period, representing 4.9% of the float. Since May 2026, short interest has increased by 168.6%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for HEMAB THERAPEUTICS HOLDINGS (COAG) currently stands at 4.3 days, down 20.3% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 248.4% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.2 to 7.5 days.
COAG Company Profile & Sector Positioning
HEMAB THERAPEUTICS HOLDINGS (COAG) operates in the Biotechnology industry within the broader Biological Products, (no Diagnostic Substances) sector and is listed on the NASDAQ. In monthly performance, the stock ranks #910 among all tracked companies.